170 related articles for article (PubMed ID: 37721526)
1. Suppression of Tumor Cell Lactate-generating Signaling Pathways Eradicates Murine PTEN/p53-deficient Aggressive-variant Prostate Cancer via Macrophage Phagocytosis.
Chaudagar K; Hieromnimon HM; Kelley A; Labadie B; Shafran J; Rameshbabu S; Drovetsky C; Bynoe K; Solanki A; Markiewicz E; Fan X; Loda M; Patnaik A
Clin Cancer Res; 2023 Dec; 29(23):4930-4940. PubMed ID: 37721526
[TBL] [Abstract][Full Text] [Related]
2. Suppression of tumor cell lactate-generating signaling pathways eradicates murine PTEN/p53-deficient aggressive-variant prostate cancer via macrophage phagocytosis.
Chaudagar K; Hieromnimon HM; Kelley A; Labadie B; Shafran J; Rameshbabu S; Drovetsky C; Bynoe K; Solanki A; Markiewicz E; Fan X; Loda M; Patnaik A
bioRxiv; 2023 May; ():. PubMed ID: 37292972
[TBL] [Abstract][Full Text] [Related]
3. Reversal of Lactate and PD-1-mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer.
Chaudagar K; Hieromnimon HM; Khurana R; Labadie B; Hirz T; Mei S; Hasan R; Shafran J; Kelley A; Apostolov E; Al-Eryani G; Harvey K; Rameshbabu S; Loyd M; Bynoe K; Drovetsky C; Solanki A; Markiewicz E; Zamora M; Fan X; Schürer S; Swarbrick A; Sykes DB; Patnaik A
Clin Cancer Res; 2023 May; 29(10):1952-1968. PubMed ID: 36862086
[TBL] [Abstract][Full Text] [Related]
4. PTEN loss and activation of K-RAS and β-catenin cooperate to accelerate prostate tumourigenesis.
Jefferies MT; Cox AC; Shorning BY; Meniel V; Griffiths D; Kynaston HG; Smalley MJ; Clarke AR
J Pathol; 2017 Dec; 243(4):442-456. PubMed ID: 29134654
[TBL] [Abstract][Full Text] [Related]
5. Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA.
Kim JS; Lee C; Bonifant CL; Ressom H; Waldman T
Mol Cell Biol; 2007 Jan; 27(2):662-77. PubMed ID: 17060456
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.
De Velasco MA; Kura Y; Yoshikawa K; Nishio K; Davies BR; Uemura H
Oncotarget; 2016 Mar; 7(13):15959-76. PubMed ID: 26910118
[TBL] [Abstract][Full Text] [Related]
7. Methylseleninic Acid Superactivates p53-Senescence Cancer Progression Barrier in Prostate Lesions of Pten-Knockout Mouse.
Wang L; Guo X; Wang J; Jiang C; Bosland MC; Lü J; Deng Y
Cancer Prev Res (Phila); 2016 Jan; 9(1):35-42. PubMed ID: 26511486
[TBL] [Abstract][Full Text] [Related]
8. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer.
Pungsrinont T; Kallenbach J; Baniahmad A
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681745
[TBL] [Abstract][Full Text] [Related]
9. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
10. Loss of phosphatase and tensin homolog (PTEN) induces leptin-mediated leptin gene expression: feed-forward loop operating in the lung.
Pathak RR; Grover A; Malaney P; Quarni W; Pandit A; Allen-Gipson D; Davé V
J Biol Chem; 2013 Oct; 288(41):29821-35. PubMed ID: 23963458
[TBL] [Abstract][Full Text] [Related]
11. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
12. PTEN- and p53-mediated apoptosis and cell cycle arrest by FTY720 in gastric cancer cells and nude mice.
Zheng T; Meng X; Wang J; Chen X; Yin D; Liang Y; Song X; Pan S; Jiang H; Liu L
J Cell Biochem; 2010 Sep; 111(1):218-28. PubMed ID: 20506484
[TBL] [Abstract][Full Text] [Related]
13. Negative cross talk between LIMK2 and PTEN promotes castration resistant prostate cancer pathogenesis in cells and in vivo.
Nikhil K; Kamra M; Raza A; Shah K
Cancer Lett; 2021 Feb; 498():1-18. PubMed ID: 32931887
[TBL] [Abstract][Full Text] [Related]
14. Androgen blockade primes NLRP3 in macrophages to induce tumor phagocytosis.
Chaudagar K; Rameshbabu S; Mei S; Hirz T; Hu YM; Argulian A; Labadie B; Desai K; Grimaldo S; Kahramangil D; Nair R; DSouza S; Zhou D; Li M; Doughan F; Chen R; Shafran J; Loyd M; Xia Z; Sykes DB; Moran A; Patnaik A
bioRxiv; 2023 Oct; ():. PubMed ID: 37904975
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of CREB binding protein-beta-catenin signaling down regulates CD133 expression and activates PP2A-PTEN signaling in tumor initiating liver cancer cells.
Tang Y; Berlind J; Mavila N
Cell Commun Signal; 2018 Mar; 16(1):9. PubMed ID: 29530069
[TBL] [Abstract][Full Text] [Related]
16. Cholesterol biogenesis is a PTEN-dependent actionable node for the treatment of endocrine therapy-refractory cancers.
Kaysudu I; Gungul TB; Atici S; Yilmaz S; Bayram E; Guven G; Cizmecioglu NT; Sahin O; Yesiloz G; Haznedaroglu BZ; Cizmecioglu O
Cancer Sci; 2023 Nov; 114(11):4365-4375. PubMed ID: 37706278
[TBL] [Abstract][Full Text] [Related]
17. E-cadherin inhibits tumor cell growth by suppressing PI3K/Akt signaling via β-catenin-Egr1-mediated PTEN expression.
Lau MT; Klausen C; Leung PC
Oncogene; 2011 Jun; 30(24):2753-66. PubMed ID: 21297666
[TBL] [Abstract][Full Text] [Related]
18. Macrophage-Derived Cholesterol Contributes to Therapeutic Resistance in Prostate Cancer.
El-Kenawi A; Dominguez-Viqueira W; Liu M; Awasthi S; Abraham-Miranda J; Keske A; Steiner KK; Noel L; Serna AN; Dhillon J; Gillies RJ; Yu X; Koomen JM; Yamoah K; Gatenby RA; Ruffell B
Cancer Res; 2021 Nov; 81(21):5477-5490. PubMed ID: 34301759
[TBL] [Abstract][Full Text] [Related]
19. Phosphatase and tensin homolog-β-catenin signaling modulates regulatory T cells and inflammatory responses in mouse liver ischemia/reperfusion injury.
Zhu Q; Li C; Wang K; Yue S; Jiang L; Ke M; Busuttil RW; Kupiec-Weglinski JW; Zhang F; Lu L; Ke B
Liver Transpl; 2017 Jun; 23(6):813-825. PubMed ID: 28152578
[TBL] [Abstract][Full Text] [Related]
20. Mammalian target of rapamycin is a therapeutic target for murine ovarian endometrioid adenocarcinomas with dysregulated Wnt/β-catenin and PTEN.
Tanwar PS; Zhang L; Kaneko-Tarui T; Curley MD; Taketo MM; Rani P; Roberts DJ; Teixeira JM
PLoS One; 2011; 6(6):e20715. PubMed ID: 21695255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]